<h1>Deployment of FDA-cleared aesthetic platforms and AI 3D skin analyser for 'Single-Day Facial Architecture', enabling proprietary marketed services</h1> The press release principally asserts regulatory compliance and marketed therapeutic scope: it states deployment of multiple FDA-cleared and CE-certified aesthetic platforms, clarifying that the technologies used carry those regulatory approvals and thereby enabling their clinical use and marketing claims in the centre. It also announces the introduction of a branded 'Single-Day Facial Architecture' protocol and an AI-powered 3D skin analyser described as 'India's first,' which constitutes a product/service positioning without statutory modification; the operative effect is to establish proprietary service offerings and marketing claims tied to those technologies and planned geographic expansion.